BBIO vs C · rev $221.9M vs P/E 16, rev $85.22B
BridgeBio Pharma Inc (BBIO) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
BBIO currently screens at market cap $13.24B. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the BBIO and C stock pages for the full models.
Not investment advice.